Why the study?
ADHD drug use in patients with known or undiagnosed heart disease may be controversial due to adverse cardiovascular effects, mainly increased blood pressure and heart rate.
This consensus statement provides structured guidance on the cardiovascular evaluation and safe use of ADHD medications in pediatric patients, including those with congenital or acquired heart disease.
Answers are grounded in this paper and cite their sources.
Provides structured guidance for CV evaluation and safe ADHD medication use in pediatric heart disease; extends prior consensus to Spanish clinical practice.
Introduction Approved drugs for attention deficit hyperactivity disorder (ADHD) in Spain are methylphenidate, lisdexamphetamine, atomoxetine and guanfacine. Due to adverse cardiovascular effects, mainly increased blood pressure and heart rate, its use in patients with known or undiagnosed heart disease may be controversial. Objective To obtain a consensus document from the Spanish Society of Paediatric Cardiology and Congenital Heart Diseases (SECPCC) and experts from other Agencies and Societies as a guide for the paediatric cardiologist and physicians who treat children and adolescents with ADHD. Method An analysis was performed on the bibliography and Clinical Practice Guidelines, technical data sheets approved by the Spanish Agency of Medicines and Health Devices, and the Spanish Ministry of Health Guidelines. A Working Group was formed, with a Coordinator, as well as members of the Clinical Cardiology Working Group and Arrhythmia Group of the SECPCC. This Group produced a preliminary document that was reviewed by a group of external experts (List 1) and a group of internal experts of the SECPCC (List 2) with a consensus being reached on the final document. Results The recommendations of the SECPCC and the group of experts are presented on cardiovascular evaluation prior to treatment in children and adolescents with unknown cardiovascular disease and with known cardiovascular disease. The recommendations of the SECPCC and the group of experts are also presented on the use of medications for ADHD in children and adolescents with cardiological symptoms with no evidence of heart disease, congenital heart disease, cardiomyopathy, Marfan syndrome and other aortic diseases, hypertension, and arrhythmias.
No takes yet. Share an insight, caveat, or question.
Picarzo et al. (2020) conducted a review in Attention deficit hyperactivity disorder (ADHD) and heart disease. ADHD medications (methylphenidate, lisdexamphetamine, atomoxetine, guanfacine) was evaluated on Consensus recommendations on cardiovascular evaluation and use of ADHD medications. The Spanish Society of Paediatric Cardiology and Congenital Heart Disease issued consensus recommendations on cardiovascular evaluation and ADHD medication use in pediatric patients with heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: